Inovio Pharmaceuticals (NASDAQ:INO) Downgraded to "Sell" Rating by Wall Street Zen

Wall Street Zen lowered shares of Inovio Pharmaceuticals (NASDAQ:INO - Free Report) from a hold rating to a sell rating in a research report report published on Saturday.

Other research analysts have also issued reports about the stock. Oppenheimer dropped their price target on shares of Inovio Pharmaceuticals from $15.00 to $13.00 and set an "outperform" rating on the stock in a research note on Wednesday, May 14th. HC Wainwright restated a "neutral" rating and set a $3.00 target price on shares of Inovio Pharmaceuticals in a research report on Wednesday, March 19th. Finally, Royal Bank Of Canada restated a "sector perform" rating and set a $5.00 target price on shares of Inovio Pharmaceuticals in a research report on Wednesday, May 14th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and two have given a buy rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Hold" and an average target price of $9.75.

Inovio Pharmaceuticals Trading Down 5.0%

Inovio Pharmaceuticals stock traded down $0.10 during trading on Friday, hitting $1.90. The company had a trading volume of 478,908 shares, compared to its average volume of 625,549. Inovio Pharmaceuticals has a 1-year low of $1.42 and a 1-year high of $12.33. The company's 50 day simple moving average is $1.93 and its 200-day simple moving average is $2.08. The stock has a market cap of $69.67 million, a price-to-earnings ratio of -0.60 and a beta of 1.34.

Inovio Pharmaceuticals (NASDAQ:INO - Get Free Report) last issued its earnings results on Tuesday, May 13th. The biopharmaceutical company reported ($0.51) EPS for the quarter, topping analysts' consensus estimates of ($0.74) by $0.23. The firm had revenue of $0.07 million for the quarter, compared to analyst estimates of $0.01 million. As a group, analysts forecast that Inovio Pharmaceuticals will post -4.23 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Inovio Pharmaceuticals

A number of hedge funds have recently made changes to their positions in the business. Wolverine Asset Management LLC acquired a new stake in Inovio Pharmaceuticals during the 4th quarter valued at $178,000. Highbridge Capital Management LLC acquired a new position in Inovio Pharmaceuticals during the 4th quarter worth $549,000. AIGH Capital Management LLC acquired a new position in Inovio Pharmaceuticals during the 4th quarter worth $1,197,000. Geode Capital Management LLC boosted its holdings in shares of Inovio Pharmaceuticals by 1.1% in the 4th quarter. Geode Capital Management LLC now owns 628,505 shares of the biopharmaceutical company's stock valued at $1,150,000 after buying an additional 6,874 shares during the period. Finally, Bank of Montreal Can acquired a new position in shares of Inovio Pharmaceuticals in the 4th quarter valued at about $43,000. Hedge funds and other institutional investors own 26.79% of the company's stock.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.